Lyon University, University Claude Bernard Lyon 1, F-69000, Lyon, France; Hospices Civils de Lyon, Neurology Department, Sclérose en Plaques, Pathologies de la Myéline et Neuro-Inflammation, F-69677, Bron, France; Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 and CNRS UMR 5292, F-69003, Lyon, France; EUGENE DEVIC EDMUS Foundation against Multiple Sclerosis, State-Approved Foundation, F-69677, Bron, France.
Hospices Civils de Lyon, Biological Ressource Center (BRIF N BB-0033-00046), F-69677, Bron, France.
Mult Scler Relat Disord. 2023 Sep;77:104872. doi: 10.1016/j.msard.2023.104872. Epub 2023 Jul 7.
Today's medicine strives to be personalized, preventive, predictive and participatory. This implies to have access to multimodal data to better characterize patients groups and to combine clinical and imaging data with high-quality biological samples. Collecting such data is one of the objectives of the Observatoire français de la sclérose en plaques (OFSEP), the French MS registry. On December 2022, the OFSEP biocollection includes 4,888 patients with scientific characteristics and about 90,000 samples. Thanks to its richness, this biocollection open for the scientific community, contributes to address unmet needs in MS through identification of multiomics determinants of MS activity, progression and secondary effects.
当今的医学致力于实现个性化、预防性、预测性和参与性。这意味着需要获取多模态数据，以更好地描述患者群体，并将临床和影像学数据与高质量的生物样本相结合。收集此类数据是 Observatoire français de la sclérose en plaques (OFSEP)，即法国多发性硬化症注册中心的目标之一。截至 2022 年 12 月，OFSEP 生物样本库包含 4888 名具有科学特征的患者和约 90000 个样本。由于其丰富性，这个向科学界开放的生物样本库通过确定多发性硬化症活动、进展和次要影响的多组学决定因素，有助于解决多发性硬化症的未满足需求。
